One paper found over 20% of patients had a deficiency after a year. A U of T pharmacist says many people now get a prescription with no follow-up support.
Recap by typeshit. Full story at Toronto Star.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
New TOGETHER-PsO data from Lilly: by week 36 the combo changed 482 proteins and 467 genes, against 140 and 16 with ixekizumab on its own.
A general rundown naming semaglutide, liraglutide and tirzepatide brands alongside promotional benefit claims. Evergreen material with nothing new in it.
Loading…